p53 serum antibodies as prognostic indicator in head and neck cancer |
| |
Authors: | J A Werner Stefan Gottschlich Benedikt J Folz Tibor Goeroegh Burkard M Lippert J-D Maass Heinrich Rudert |
| |
Institution: | (1) Department of Otorhinolaryngology, Head and Neck Surgery, Christian-Albrechts-University, Arnold-Heller-Str. 14, 24105 Kiel, Germany Fax: 0049 431 597–2272, DE |
| |
Abstract: | p53 antibodies are a new serological parameter of unknown potential in patients with malignancies. Their occurrence has been
described in various types of cancer patients. The mechanism underlying the immunization process is still unclear. We investigated
the incidence of p53 serum antibodies in 143 head and neck cancer patients with an enzyme-linked immunosorbent assay. The
post-therapy course of two matched study groups (n = 38 each), one p53-antibody-seropositive and one p53-antibody-seronegative, was followed up for 24 months. Thirty-nine head
and neck cancer patients (27.3%) were seropositive for p53 antibodies. During the follow-up, the p53-antibody-seropositive
patients accounted for more local tumor recurrences (n = 12 versus n = 8) and more tumor-related deaths (n = 11 versus n = 5) than did seronegative patients, and second primary tumors (n = 9 versus n = 0) occurred exclusively in seropositive patients. In total, therapy failures (recurrences, tumor-related deaths,
second primaries) were observed in 17/38 cases (44.7%) in the p53-antibody-seropositive group and in 8/38 cases (21.1%) in
the p53-antibody-seronegative group. These results, after a follow-up of 2 years, seem to indicate a prognostic value of p53
serum antibodies for therapy failure in patients with head and neck cancer.
Received: 5 December 1996 / Accepted: 4 January 1997 |
| |
Keywords: | p53 serum antibodies Prognostic indicator Head and neck cancer |
本文献已被 SpringerLink 等数据库收录! |
|